engleski

Collegium Internationale Neuro-Psychopharmacologicum -23rd Congress (Part III)- Montreal, Canada, 23-27 June 2002

The congress was well organized, however there was a feeling that some important experts were missing, with not so adequate replacements, and that there was not a lot of new data presented at the congress. The congress's topics were depression, schizophrenia, PTSD, AD, panic disorders, GAD, attention deficit/hyperactivity disorders, alcoholism, bipolar disorders, and eating disorders. Some new theories were introduced, like the antidepressant effect of smoking in MDD, or some new combinations of drugs in the treatment of depression, like the combinations of SSRIs with atypical antypsychotics, in the treatment of depression, and in nonpsychotic but treatment resistant PTSD (SSRI with olanzapine), and some potentially new antidepressants, like SPAs. The congress covered also the side effects of psychotropic drugs, especially effects on plasma lipids and plasma glucose, metabolic parameters associated to insulin resistance, and possibly comorbid diabetes mellitus, and antidepressants and cardiac drug interactions

NK1receptor antagonists; SSR-149415; AR-A000002; new drug combinations; serotonin augmentation strategy; antipsychotics

nije evidentirano